The Anti-Infectives Market Outlook to 2013:


Competitive landscape, pipeline analysis and growth opportunities

Pages: 211

Publisher: Business Insights

Date Published: August 2008

Format: PDF

Price: $3835

Overview

The Global ‘Anti-infectives Market Outlook to 2013’ provides comprehensive coverage of the anti-infectives market, incorporating the disease overview and detailed epidemiological analysis of the major indications. This report analyzes the marketed product portfolio, in-depth R&D pipeline analysis, market share data, sales forecast and the competitive landscape for the major players.

Table of Contents

Executive Summary 12
Disease overview and epidemiology 12
Global market analysis 13
Pipeline analysis 14
Competitive landscape 15

Chapter 1 Scope and methodology 18
Scope 18
Key drug-classes covered in this report 18
Methodology 19

Chapter 2 Disease overview and epidemiology 22
Summary 22
Introduction 23
Bacterial infections 24
Overview 24

  • Respiratory tract infections 24

  • Urinary tract infections 25

  • Skin and skin structure infections 25

Pharmacological treatment 25

  • Penicillins 26

  • Cephalosporins 26

  • Quinolones 26

  • Macrolides 27

  • Vaccines 28

Estimated incidence of bacterial infections 30

  • Respiratory tract infections 30

  • Urinary tract infections 32

  • Skin and skin structure infections 33

Forecast epidemiology 34

  • Respiratory tract infections 34

  • Urinary tract infections 36

  • Skin and skin structure infections 37

Viral infections 38

AIDS/HIV 38

  • Pharmacological treatment 38

  • Estimated incidence of HIV 40

Hepatitis 41

  • Pharmacological treatment for hepatitis 42

  • Estimated incidence of Hepatitis 45

  • Forecast epidemiology 47

Influenza 49

  • Pharmacological treatment for influenza 50

  • Estimated incidence of Influenza 50

Herpes 51

  • Pharmacological treatment for herpes 52

  • Estimated incidence of herpes 53

  • Forecast epidemiology 55

Other viral infections 57

  • Human papillomavirus 57

  • Rotavirus 58

Fungal infections 59

  • Pharmacological treatment for fungal infections 60

  • Estimated incidence of fungal infections 60

  • Forecast epidemiology 62

Chapter 3 Global market analysis 66
Summary 66
Introduction 67
Market analysis by country 67
Licensing trends 68
Market analysis by drug classes 69
Leading brands dynamics 71
Key events in the anti-infectives market 72
Modest growth from Quinolones 72
Drug resistant infections confer long term growth opportunity 73
Novel HIV/AIDS drugs present substantial market opportunity 73
Hepatitis C therapies fuel strong growth through 2013 73
Novel vaccines drive future sales growth 74
Global concerns on potential human avian flu epidemic 74
Anti-bacterials 75
Market analysis by drug class 75
Leading brands of anti-bacterial treatments 76

Cephalosporins 77

  • Key brand analysis 78

Penicillins 78

  • Key brand analysis 80

Fluoroquinolones 80

  • Key brand analysis 82

Macrolides 84

  • Key brand analysis 85

Carbapenems 86

  • Key brand analysis 87

Tetracyclines 88

  • Key brand analysis 89

Other antibiotics 90

  • Key brand analysis 92

Anti-bacterials sales forecast (2008–2013) 93

Anti-virals 96
Breakdown of the global anti-virals market 96
Leading brands of anti-virals treatment 97

  • Key brand analysis 98

Anti-virals sales forecasts (2008 – 2013) 100

Vaccines 101
Breakdown of the global vaccines market 101
Leading brands of vaccines 101

  • Key brand analysis 103

Vaccines sales forecasts 2008–2013 105

Anti-fungals 106
Breakdown of the global anti-fungals market 106
Leading brands of anti-fungals treatment 107

  • Key brand analysis 109

Anti-fungals sales forecasts 2008-2013 111
Total anti-infective market sales forecasts to 2013 112

Chapter 4 Pipeline analysis 114
Summary 114
Introduction 115
Key trends in R&D 115
Key trends in the anti-bacterial market 116
Key trends in the anti-viral market 118
Key trends in the vaccines market 118
Key trends in the anti-fungal market 119
Therapeutic area pipeline 120
Leading drugs in development 122
Profiles of key pipeline products 123

Recently marketed drugs 123

  • Doribax 123

  • Isentress 125

  • Prezista 127

  • Selzentry 129

  • Eraxis 131

  • Gardasil 133

Drugs in registration 135

  • Ceftobiprole 135

  • Cervarix 137

Drugs in phase III clinical studies 139

  • Albuferon 139

  • Tygacil 141

  • Numax 143

  • Telaprevir 145

  • Vicriviroc 147

  • Menveo 149>/li>
  • Prevnar 13vPnC 150

Pipeline forecast 152

  • Factors affecting forecasts 152

  • Anti-bacterials 152

  • Anti-virals 153

  • Anti-fungals 154

  • Vaccines 155

Chapter 5 Competitive landscape 158
Summary 158
Introduction 159
Sales performance among the leading players 159
Detailed analysis of leading anti-infective players 163

GlaxoSmithKline 163

  • Overview 163

  • Sales focus by drug class 164

  • Marketed product portfolio 165

  • R&D pipeline analysis 166

  • Strategic and growth analysis 167

Merck 168

  • Overview 168

  • Sales focus by drug class 168

  • Marketed product portfolio 169

  • R&D pipeline analysis 171

  • Strategic and growth analysis 172

Pfizer Overview 172

  • Sales focus by drug class 173

  • Marketed product portfolio 174

  • R&D pipeline analysis 175

  • Strategic and growth analysis 176

Novartis 177

  • Overview 177

  • Sales focus by drug class 178

  • Marketed product portfolio 179

  • R&D pipeline analysis 180

  • Strategic and growth analysis 181

Gilead Sciences 183

  • Overview 183

  • Sales focus by drug class 183

  • Marketed product portfolio 184

  • R&D pipeline analysis 184

  • Strategic and growth analysis 186

Abbott 187

  • Overview 187

  • Sales focus by drug class 187

  • Marketed product portfolio 188

  • R&D pipeline analysis 189

  • Strategic and growth analysis 190

Wyeth 190

  • Overview 190

  • Sales Focus By Drug class 191

  • Marketed Product Portfolio 192

  • R&D pipeline analysis 194

  • Strategic and growth analysis 195

Sanofi-Aventis 196

  • Overview 196

  • Sales focus by drug class 197

  • Marketed product portfolio 198

  • Strategic and growth analysis 200

Bristol-Myers Squibb 201

  • Overview 201

  • Sales focus by drug class 201

  • Marketed product portfolio 202

  • R&D pipeline analysis 203

  • Strategic growth analysis 203

Johnson & Johnson 204

  • Overview 204

  • Sales focus by drug class 205

  • Marketed product portfolio 206

  • R&D pipeline analysis 207

  • Strategic growth analysis 208

IMS data 210
J1 Systemic antibiotics 210
J2 Systemic agents for fungal infections 210
J5 Antivirals for systemic use 210
J7 Vaccines 210

Index 211

List of Figures

Figure 3.1: Global anti-infectives market share by geography (%), global, 2007 67
Figure 3.2: Sales revenuesof anti-infectives by licensing status ($m), global, 2006–2007 68
Figure 4.3: Key trends in the anti-infectives R&D pipelines, 2007-2013 115
Figure 4.4: Anti-infectives pipeline by indication and stage of development, March 2008 120
Figure 4.5: Leading drugs in development, March 2008 122
Figure 4.6: Anti-bacterial pipeline forecast, 2007–2013 152
Figure 4.7: Anti-viral pipeline forecast, 2007–2013 153
Figure 4.8: Anti-fungal pipeline forecast, 2007–2013 154
Figure 4.9: Vaccines pipeline forecast, 2007–2013 155
Figure 5.10: Market share of key players by sales revenues, 2007 160
Figure 5.11: Forecast market share of leading anti-infectives players by sales revenues, 2013 161
Figure 5.12: Market share and ranking of leading players in the global anti-infectives market, 2007 – 2013 162
Figure 5.13: GSK’s anti-infectives product portfolio by drug class, 2007 164
Figure 5.14: Merck’s anti-infectives product portfolio by drug class, 2007 169
Figure 5.15: Pfizer’s anti-infectives product portfolio by drug class, 2007 173
Figure 5.16: Novartis anti-infectives product portfolio by drug class, 2007 178
Figure 5.17: Gilead Science’s anti-infectives product portfolio by drug class, 2007 183
Figure 5.18: Abbott’s anti-infectives product portfolio by drug class, 2007 187
Figure 5.19: Wyeth’s anti-infectives product portfolio by drug class, 2007 191
Figure 5.20: Sanofi-Aventis’ anti-infectives product portfolio by drug class, 2007 197
Figure 5.21: Bristol –Myers Squibb’s anti-infectives product portfolio by drug class, 2007 201
Figure 5.22: J&J’s anti-infectives product portfolio by drug class, 2007 205

List of Tables

Table 2.1: Estimated incidence of infective diseases, EU5, US and Japan, 2005 23
Table 2.2: Estimated incidence of community acquired pneumonia infections EU5, US and Japan,
2007 30
Table 2.3: Estimated incidence of upper RTIs caused by streptococcus infection, EU5, US and
Japan, 2007 31
Table 2.4: Estimated incidence of community acquired urinary tract infections, EU5, US and
Japan, 2007 32
Table 2.5: Estimated incidence of bacterial skin and skin structure infections, EU5, US and
Japan, 2007 33
Table 2.6: Forecast epidemiology of CAP, EU5, US and Japan, 2007–2013 34
Table 2.7: Forecast epidemiology of uRTIs caused by streptococcus infection, Eu5, US and
Japan, 2007–2013 35
Table 2.8: Forecast epidemiology of urinary tract infections, EU5, US and Japan, 2007–2013 36
Table 2.9: Forecast epidemiology of skin and skin structure infections, EU5, US and Japan,
2007–2013 37
Table 2.10: HIV/AIDS incidence and prevalence ($m), 2005 40
Table 2.11: Estimated incidence of community acquired HBV and HCV infection (‘000s), EU5,
US and Japan, 2007 45
Table 2.12: Forecast epidemiology of HBV, EU5, US and Japan, 2007–13 47
Table 2.13: Forecast epidemiology of HCV, EU5, US and Japan, 2007–13 48
Table 2.14: Estimated seroprevalence of HSV – 1 and HSV – 2 infections (‘000s), Eu5, US and
japan, 2007 53
Table 2.15: Forecast seroprevalence of HSV 1, EU5, US and Japan, 2007–13 55
Table 2.16: Forecast seroprevalence of HSV 2 across the seven major markets, 2007–2013 56
Table 2.17: Estimated incidence of systemic fungal infections (‘000s) in EU5, US and Japan, 2007
61
Table 2.18: Forecast epidemiology of systemic fungal infections, EU5, US and Japan, 2007–2013
62
Table 3.19: Breakdown of the global anti-infectives market by drug class ($m), 2006–2007 69
Table 3.20: Leading brands in the global anti-infectives market ($m), 2006–2007 71
Table 3.21: Breakdown of the global anti-bacterial market by drug class ($m), 2006–2007 75
Table 3.22: Leading anti-bacterials in the global anti-infectives market ($m), 2006–2007 76
Table 3.23: Leading cephalosporins in the global anti-infectives market ($m), 2006–2007 77
Table 3.24: Leading penicillins in the global anti-infectives market ($m), 2006–2007 79
Table 3.25: Leading fluoroquinolones in the global anti-infectives market ($m), 2006–2007 81
Table 3.26: Leading macrolides in the global anti-infectives market ($m), 2006–2007 84
Table 3.27: Leading carbapenems in the global anti-infectives market ($m), 2006–2007 86
Table 3.28: Leading tetracyclines in the global anti-infectives market ($m), 2006–2007 88
Table 3.29: Leading other anti-bacterials in the global anti-infectives market ($m), 2006–2007 90
Table 3.30: Anti-bacterials sales forecast ($m), global, 2008–2013 93
Table 3.31: Anti-bacterials sales forecast ($m), global, 2008–2013 (continued) 94
Table 3.32: Anti-bacterials sales forecast ($m), global, 2008–2013 95
Table 3.33: Breakdown of the global anti-virals market by drug class ($m), 2006–2007 96
Table 3.34: Leading antivirals in the global anti-infectives market ($m), 2006–2007 97
Table 3.35: Anti-virals sales forecast ($m), global, 2008-2013 100
Table 3.36: Breakdown of the global vaccines market by class ($m), 2006–2007 101
Table 3.37: Leading vaccines in the global anti-infectives market ($m), 2006–2007 102
Table 3.38: Global vaccines sales forecast, 2008–2013 ($m) 105
Table 3.39: Global anti-fungal market, ($m), 2006–2007 106
Table 3.40: Leading anti-fungal brands in the global anti-infectives market ($m), 2006–2007 107
Table 3.41: Global anti-fungals sales forecast ($m), 2008–2013 111
Table 3.42: Global anti-infectives sales forecast ($m), 2008–2013 112
Table 4.43: Key drug profile, Doripenem 123
Table 4.44: An overview on Isentress 125
Table 4.45: An overview on Prezista 127
Table 4.46: An overview on Selzentry 129
Table 4.47: An overview on Eraxis 131
Table 4.48: An overview on Gardasil 133
Table 4.49: FDA approvals and NDA filings of Gardasil 134
Table 4.50: An overview on Ceftobiprole 135
Table 4.51: An overview on Cervarix 137
Table 4.52: An overview on Albuferon 139
Table 4.53: An overview on Tygacil 141
Table 4.54: An overview on Motavizumab 143
Table 4.55: An overview on Telaprevir 145
Table 4.56: An overview on Vicriviroc 147
Table 4.57: An overview on Menveo 149
Table 4.58: An overview on Prevna13vPnC 150
Table 5.59: Sales performance of the leading players in the global anti-infectives market ($m),
2006–2007 159
Table 5.60: GSK’s leading anti-infectives product sales ($m), 2006–2007 165
Table 5.61: GSK’s anti-infectives product pipeline, 2006–2007 166
Table 5.62: Merck’s leading anti-infectives product sales ($m), 2006–2007 170
Table 5.63: Merck’s anti-infectives product pipeline, 2006–2007 171
Table 5.64: Pfizer’s anti-infectives product portfolio, 2006–2007 ($m) 174
Table 5.65: Pfizer’s anti-infectives product pipeline, 2006–2007 175
Table 5.66: Novartis’ anti-infectives product portfolio, 2006–2007 ($m) 179
Table 5.67: Novartis’ anti-infectives product pipeline, 2006–2007 180
Table 5.68: Gilead Sciences’ leading anti-infectives product sales, 2006–2007 ($m) 184
Table 5.69: Gilead Sciences’ anti-infectives product pipeline, 2006–2007 185
Table 5.70: Abbott’s leading anti-infectives product sales, 2006–2007 ($m) 188
Table 5.71: Abbott’s anti-infectives product pipeline, 2006–2007 189
Table 5.72: Wyeth’s leading anti-infectives product sales, 2006–2007 192
Table 5.73: Wyeth’s anti-infectives product pipeline, 2006–2007 194
Table 5.74: Sanofi-Aventis’ leading anti-infectives product sales, 2006–2007 ($m) 198
Table 5.75: Sanofi-Aventis’ anti-infectives product pipeline, 2006–2007 199
Table 5.76: Bristol –Myers Squibb’s leading anti-infectives product sales, 2006–2007 ($m) 202
Table 5.77: Bristol –Myers Squibb’s anti-infectives product pipeline, 2006–2007 203
Table 5.78: J&J’s leading anti-infectives product sales, 2006–2007 ($m) 206
Table 5.79: J&J’s anti-infectives product pipeline, 2006–2007 207